Celgene Stock

CELG

Delayed Nasdaq 16:00:00 2019-11-20 EST			5-day change	1st Jan Change
108.24 ^USD	+0.10%		-1.97%	+68.89%

23-06-14	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
21-09-07	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI

News in other languages: Celgene

21-04-07	DGAP-WpÜG: Angebot zum Erwerb / Zielgesellschaft: ; Bieter: qqqqq
21-03-25	Leonteq wird neue Emittentin an der BX Swiss AG im Segment «deriBX»
21-02-02	BX Swiss AG startet Handel in neuem Bondsegment
20-07-07	Die BX Swiss AG erhält von der FINMA die Zulassung zur Führung des Schweizer Beraterregisters
20-07-03	Möbel Markt mömax wird neuer Ankermieter im Rüti Center in Pratteln

More news

Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).

Employees

Sector

More about the company

Market Cap	77.04B 66.54B 62.52B 56.86B 107B 7,366B 109B 733B 286B 3,689B 289B 283B 12,259B	P/E 2017	28.7x	P/E 2018	11.6x
Enterprise Value	91.26B 78.82B 74.07B 67.36B 127B 8,726B 129B 868B 339B 4,370B 343B 335B 14,521B	EV / Sales 2017	6.61x	EV / Sales 2018	3.86x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

23-06-14	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
21-09-07	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI
21-06-21	Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity	CI
21-02-22	Celgene Corporation Issues Notice of Redemption of Notes	CI
21-02-04	Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion	CI
21-01-04	Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors	CI
20-12-22	Amgen : Signs Licensing Agreement With Medicines Development for Global Health	MT
20-11-05	Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook	MT
20-09-22	Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors	CI
20-09-21	Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors	CI
20-03-25	Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene	CI
20-03-10	Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors	CI
20-03-04	Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis	CI

23-02-28	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
22-08-24	Not What The Doctor Ordered: Authorisation Application Withdrawn For Pharma Patent Settlement In Australia	AQ
22-07-29	Authorisation request for proposed settlement between pharmaceutical companies withdrawn	AQ
22-02-24	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
21-08-04	Celgene : Sun Pharma And Celegene Settle Patent Dispute Over Lenalidomide (Revlimid®)	AQ

	2017	2018
Net sales	13B 11.23B 10.55B 9.6B 18.04B 1,243B 18.34B 124B 48.35B 623B 48.82B 47.76B 2,069B	15.28B 13.2B 12.4B 11.28B 21.21B 1,461B 21.56B 145B 56.82B 732B 57.37B 56.13B 2,432B
Net income	2.94B 2.54B 2.39B 2.17B 4.08B 281B 4.15B 27.96B 10.93B 141B 11.04B 10.8B 468B	4.05B 3.49B 3.28B 2.99B 5.61B 387B 5.71B 38.48B 15.04B 194B 15.19B 14.86B 644B
Net Debt	3.79B 3.28B 3.08B 2.8B 5.26B 363B 5.35B 36.07B 14.1B 182B 14.24B 13.93B 604B	14.22B 12.28B 11.54B 10.5B 19.73B 1,360B 20.06B 135B 52.88B 681B 53.39B 52.23B 2,263B

Celgene Stock

Stocks

CELG

Valuation: Celgene

Latest news : Celgene

Press Releases: Celgene

News in other languages: Celgene

Quotes and Performance

Financials

Company Profile